Spots Global Cancer Trial Database for Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer

Official Title: Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer

Study ID: NCT05767931

Conditions

Invasive Breast Cancer

Interventions

Study Description

Brief Summary: This is a prospective, single-center, non-randomized, non-controlled study

Detailed Description: Immunotherapy with immune-checkpoint inhibitors (ICIs) has enabled a leap forward in the treatment of various types of cancer within the past decade. However,only 12.46% of patients with cancer are expected to respond to ICIs.Our team have recently developed a multi-specific antibody technology platform for the microenvironment of solid tumors. In this study, we are going to study the tumor immune microenvironment of breast cancer patients by patient-derived organoids or PDX model，to design multi-specific antibody drugs for different tumor immune microenvironment，to look forward to improve the effectiveness of immunotherapy for breast cancer and solve the problem of drug resistance.